Great news from IgGenix, the company using its SEQ SIFTER platform to develop treatments for food allergies. They have uncovered antibodies implicated in Alpha-gal Syndrome, work providing insights that may lead to therapies and a cure. #foodallergies
snacksafely.com/2025/02/igge...

IgGenix flips the biology of allergy on its head: it finds the antibody that makes you sick, then rebuilds it into one that protects you.

https://yespress.io/iggenix-inc?utm_source=bluesky&utm_medium=social via Yespress - apply for company newsroom: yespress.io/newsroom

A couple new updates on clinical trials in peanut allergy and immune diseases.

IgGenix Australia is recruiting in for a clinical trial of their treatment for peanut allergy. They isolated IgE mAbs and class-switched them to igG4 mAbs.
www.iggenix.com.au
pubmed.ncbi.nlm.nih.gov/39069172/
1/

🔗 The study is currently recruiting participants. To learn more and check your eligibility, visit- allergylife.com.au/iggenix

-𝘛𝘩𝘪𝘴 𝘪𝘴 𝘯𝘰𝘵 𝘢 𝘴𝘱𝘰𝘯𝘴𝘰𝘳𝘦𝘥 𝘱𝘰𝘴𝘵

𝘈𝘭𝘭𝘦𝘳𝘨𝘺 𝘓𝘪𝘧𝘦 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘴 𝘢𝘭𝘭𝘦𝘳𝘨𝘺 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘵𝘳𝘪𝘢𝘭𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥 𝘵𝘰 𝘬𝘦𝘦𝘱 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥.

🔬Study Overview-
• Name of Research Study: IgGenix ACCELERATE Peanut Study
• Area of Allergy Research: Food Allergies (Peanuts)
• Research for: Teens and Adults (15 to 55)
• Location of Study: Western Australia, New South Wales and Victoria

#peanutallergy #peanutallergies #iggenix

IgGenix to Showcase Groundbreaking Alpha-gal Antibody Discovery at 2025 AAAAI / WAO Congress#United_States#San_Diego#Monoclonal_Antibodies#IgGenix#Alpha-gal_Syndrome

IgGenix is using its new RNA-sequencing platform to accelerate the development of allergy treatments, starting with peanut allergy. #foodallergies